Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Overview of attention for article published in PharmacoEconomics, March 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 47 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,187 followers.

New BUSINESS Research Available. Click Here to Access Article(s): https://t.co/2aFjc09Lq1

27 Jul 2020

Reply Repost Favourite

Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. #lymphoma #lymsm https://t.co/J8vgLOdzSZ

22 Mar 2019

Reply Repost Favourite

#HealthEconJA Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal https://t.co/liuQRatiTC

21 Mar 2019

Reply Repost Favourite